anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A Phase II Randomized Controlled Open-Label Parallel Group Interventional Multicenter Trial. Patients with metastatic melanoma, stratified for stage M1a or M1b/M1c, that have received first-line treatment with PD-1 inhibitors for a minimum of 9 months resulting in either partial response or stable disease according to RECIST 1.1 will be eligible. Patients will be screened for operability based on CT-scans examined by a multidisciplinary team, with the criteria that complete (R0) resection of all metastases should be possible. If the multidisciplinary team find that this would be possible, patients will be included and randomized 1:1 to either surgery with continued PD1-inhibition or current standard of care with continued PD1-inhibition only. At progression, treatment will be according to the treating medical oncologist. Active follow-up will be performed for 12 months.
Consented parents of a concussed high school student who will receive CDC Head's UP Concussion Guidelines during a five week program. 75 Participants.
To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to method for enhancement of bioavailability of taxane in oral administration in combination with cyclosporin, to method for treatment of diseases showing sensitivity to taxane and, respectively, oral pharmaceutical medicinal formula. Invention provides the increase of square under pharmacokinetic curve of docetaxel from 8% after independent intake per os to 90% after the combined administration with cyclosporin A due to not only effect on cytochrome P-450 (isoform 3A4) but by inhibition of glycoprotein-P in digestive tract mucosa also. This allows the enhancement of effectiveness of taxane sharply in the proposed medicinal formula combined with cyclosporin and effectiveness of treatment of disease that is sensitive to taxane. EFFECT: enhanced and valuable medicinal properties of method and compositions. 53 cl, 10 tbl, 13 ex
PURPOSE: To obtain the stable suspension-like pharmaceutical composition comprising a particulate active substance and a microfine filler having a specific particle size distribution, not containing a thickening ancillary, gradually precipitating, not generating a cement-like agglutination and having a good taste. CONSTITUTION: A pharmaceutical composition in the form of cefiximecontaining, non-aqueous suspension which has syrup-like characteristics. Namely, the composition is free of thickening ancillary substances, contains a microfine powder of a bulking agent with a particle size distribution in which the powder having a maximum diameter of 32 μm and the powder having a minimum diameter of 50 μm are contained in amounts of at least 80 wt.% and at most 5 wt.%, respectively, is very easily redispersible, is chemically stable, and contains the cefixime as active ingredient as particles. The particulate active ingredient is preferably contained in an amount of 0.1-5 wt.%. The particulate active ingredient may be suspended in the triglyceride of a fatty acid having an approximately middle molecular chain length.  The suspension may further contain a wetting agent in a concentration of 0.01-1 wt.%.
Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
The invention discloses a traditional Chinese medicine composition for treating hiccups after tumor radiotherapy. A traditional Chinese medicine preparation is prepared from rhizomes of david woodbetony, redflower peasthrub roots, woodland beakchervil roots, jenkine dendrobium, oreas martiana (hopp. et hornsch.) brid, phloem of trunk of eriobotrya japonica (thunb.) lindl., grass node in stomach of ox, wintersweet flowers, fiverleaf akebia fruits, melitodes squamata nutting and pyropolyporus fomentarius (L. ex Fr.) teng. The traditional Chinese medicine compositions for treating hiccups after tumor radiotherapy can alleviate hiccup symptoms rapidly and is free of side effects and special medicine for treating hiccups after tumor radiotherapy. Decoction of the traditional Chinese medicine compositions for treating hiccups after tumor radiotherapy is adopted for treating 40 patients for 1-2 weeks, the total effective rate of a treatment group is 94.29%, the total effective rate of a control group is 71.43%, and the total effective rate of the treatment group is obviously superior to that of the control group (P is less than 0.05).
The objective of this study is to estimate the safety and performance of Journey II BCS TKS. Specifically, the study will establish revision rate, treatment- and device-related complications, and clinical outcomes in a large sample of subjects who received the study device. Subjects are screened consecutively, beginning at the earliest date of implantation at each investigative site. Further, reasons for revision will be collected and analyzed. An analysis will be performed to identify characteristics (patient, surgeon and surgical) associated with an increased risk for revision. Finally, clinical, functional and quality of life outcomes will be analyzed to the extent data is available, given the retrospective study design.
The invention relates to an immunoadsorbent for treating PLA2R type membranous nephropathy. The immunoadsorbers include a fusion protein; wherein the fusion protein comprises: a neutral antibody comprising an antibody FC segment or a first antibody, one or more PLA2R epitope peptides, said PLA2R epitope peptides linked to said neutral antibody; the first antibody comprises CDR sequences selected from at least one of the following: light chain variable region CDR sequences: SEQ ID NO. 1-3, SEQ ID NO. 7-9 and SEQ ID NO. 83-85, heavy chain variable region CDR sequence: SEQ ID NO 4-6, SEQ ID NO 10-12, SEQ ID NO 86-88 and SEQ ID NO 89-91. The immunoadsorbent of the present invention can adsorb PLA2R antibodies, which can effectively treat diseases related to PLA2R antibodies, such as PLA2R antibody positive membranous nephropathy, by immunoadsorption.
A dramatic rise in self-tracking applications for smartphones has occurred recently. Rich user interfaces make manual logging of users' behavior easier and more pleasant; sensors make tracking effortless. To date, however, feedback technologies have been limited to providing counts or attractive visualization of tracked data. Human experts (health coaches) have needed to interpret the data and tailor make customized recommendations. No automated recommendation systems like Pandora, Netflix or personalized search for the web have been available to translate self-tracked data into actionable suggestions that promote healthier lifestyle without needing to involve a human interventionist.

MyBehavior aims to fill this gap. It takes a deeper look into physical activity and dietary intake data and reveal patterns of both healthy and unhealthy behavior that could be leveraged for personalized feedback. Based on common patterns from a user's life, suggestions are created that ask users to continue, change or avoid existing behaviors to achieve certain fitness goals. Such an approach is different from existing literature in two important aspects: (1) suggestions are contextualized to a user's life and are built on existing user behaviors. As a result, users can act on these suggestions easily, with minimal effort and interruption to daily routines; (2) unique suggestions are created for each individual. This personalized approach differs from traditional one-size-fits-all or targeted intervention models where identical suggestions are applied for groups of similar people or the entire population.
The study is based on a random sampling of 100 taxi drivers, working full-time day shift, in Paris, members of three Trade Unions. It will be conducted over a period of two years in warm and cold season. The research will begin with an inclusion clinical examination. It consists on determining the overall health status of the participants by administering a standardized questionnaire and performing spirometry test, prick test and FENO measurement. The exposure assessment will be based on continuous measurement of UFP, BC, carbon monoxide (CO) and NO2, by portable devices during a working day (± 11 hours). On the same day, two spirometry tests and two measurements of exhaled carbon monoxide will be performed at the beginning and at the end of the shift, using handheld devices. Multivariate analysis will provide spatio-temporal distributions of individual exposures and their determinants. Generalized Estimating Equations (GEE) multivariate models will be used to determine the relation between exposure (UFP, BC) and respiratory symptoms, ventilation performances, adjusting for potential confounding/modifying factors.
MindEx consists of two Neuroport Multi-Port Arrays, described in detail in the intervention description. Each NeuroPort Multi-Port Array comprises two electrode arrays implanted into human brain tissue, for a total of four electrode arrays. These will be in 1) prefrontal cortex, a brain area involved in scene comprehension, action selection, and error signaling, 2) premotor cortex, a brain area involved in planning ongoing and upcoming actions, 3) posterior parietal cortex, a brain area involved in processing sensory-to-motor transformations during movements, and 4) primary motor cortex, responsible for controlling movement. The pair of electrode arrays in each NeuroPort Multi-Port Array connect to a single percutaneous pedestal attached to the skull during a surgical procedure. Following recovery from the surgical placement, subjects will participate in study sessions up to 5 times a week. They will learn to use thought to control applications on a computer, a laptop, or a tablet.
To evaluate the predictive factors affecting the stone-free rate (SFR) and complications of percutaneous nephrolithotomy (PCN) in the treatment of proximal impacted ureteral stones (PIUS) based on a new scoring standard. The data of 90 patients with PIUS were collected in this retrospective study between January 2015 and June 2023. Univariate and multivariate logistic regression analyses were used to determine factors affecting treatment outcome in terms of SFR and complications. The scoring standard for patients with PIUS was developed based on the univariate logistic regression analyses. In the univariate analysis, stone density (P = 0.015), and stone diameter (P = 0.032) significantly were associated with lower SFR. And degree of hydronephrosis (P = 0.014), Preoperative infection (P = 0.002), and history of lithotripsy (P = 0.045) were associated with occurrence of complications. Multivariate analysis indicated that stone density (P = 0.020), and stone diameter (P < 0.001) were associated with lower SFR; independent risk factors for development of complications were history of lithotripsy (P = 0.024), and preoperative infection (P < 0.001). Additionally, score ≥ 3 was the independent risk factor for both SFR (P < 0.001) and complication rate (P < 0.001). Subgroup analysis shown that there were statistically significant differences between the two groups in terms of stone-free rate (P = 0.032) and complications (P = 0.015). According to the findings of this study, the stone score ≥ 3 was determined as a critical predictive factor of SFR and complications in PIUS patients undergoing PCN based on a new scoring standard. Additionally, PCN has high initial SFR and low complications when dealing with score < 3 PIUS.
Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
Participants will receive "real" tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions.
RATIONALE: Elevated levels of CD11c+ myeloid cells are observed in various pulmonary disorders, including Idiopathic Pulmonary Fibrosis (IPF). Dendritic cells (DCs) and macrophages (MΦ) are critical antigen-presenting cells (APCs) that direct adaptive immunity. However, the role of CD11c+ myeloid cells in lung extracellular matrix (ECM) accumulation and pulmonary fibrosis is poorly understood.
OBJECTIVE: We aimed to investigate the impact of depleting CD11c+ myeloid cells, including DCs and macrophages, during bleomycin-induced pulmonary fibrosis in mice.
METHODS: We used a diphtheria toxin (DTx) receptor (DTR) transgenic mouse model (CD11c-DTR-Tg) to deplete CD11c+ myeloid cells through two methods: Systemic Depletion (SD) via intraperitoneal injection (i.p.) and local depletion (LD) via intranasal instillation (i.n.). We then assessed the effects of CD11c+ cell depletion during bleomycin-induced lung inflammation and fibrosis.
RESULTS: Fourteen days after bleomycin instillation, there was a progressive accumulation of myeloid cells, specifically F4/80-MHCII+CD11c+ DCs and F4/80 + MHCII+CD11c+ MΦ, preceding mortality and pulmonary fibrosis. Systemic depletion of CD11c+ DCs and MΦ via i.p. DTx administration in CD11c-DTR-Tg mice protected against bleomycin-induced mortality and pulmonary fibrosis compared to wild-type (WT) mice. Systemic depletion reduced myeloid cells, airway inflammation (total leukocytes, neutrophils, and CD4+ lymphocytes in bronchoalveolar lavage (BAL), inflammatory and fibrogenic mediators, and fibrosis-related mRNAs (Collagen-1α1 and α-SMA). Increased anti-inflammatory cytokine IL-10 and CXCL9 levels were observed, resulting in lower lung hydroxyproline content and Ashcroft fibrosis score. Conversely, local depletion of CD11c+ cells increased mortality by acute leukocyte influx (predominantly neutrophils, DCs, and MΦ in BAL) correlated to IL-1β, with lung hyper-inflammation and early fibrosis development.
CONCLUSION: Systemic depletion of CD11c+ cells confers protection against inflammation and fibrosis induced by Bleomycin, underscoring the significance of myeloid cells expressing F4/80-MHCII+CD11c+ DCs and F4/80 + MHCII+CD11c+ MΦ orchestrating the inflammatory milieu within the lungs, potentially as a source of cytokines sustaining pulmonary chronic inflammation leading to progressive fibrosis and mortality.
Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
PURPOSE OF REVIEW: Pediatric cochlear implantation has evolved considerably over the past three decades to include more patients at earlier ages with greater degrees of residual hearing. As an extension, a significant focus of research over the past decade has surrounded preservation of existing acoustic hearing.
RECENT FINDINGS: Multiple studies published within the last 5 years demonstrate aidable acoustic hearing preservation in 60-90% of pediatric patients, with 40-60% experiencing complete hearing preservation following cochlear implantation. Durability of preserved hearing varies among patients, with some patients losing residual hearing within 1 year of surgery whereas others maintain acoustic hearing through at least 5 years of follow-up. Speech outcomes appear superior among patients with preserved acoustic hearing, particularly in the presence of background noise. Several recent studies suggest a music appreciation advantage in children with preserved acoustic hearing following cochlear implantation.
SUMMARY: Hearing preservation rates during cochlear implantation in children matches, if not often exceeds, hearing preservation rates observed among adults. Preservation of acoustic hearing during cochlear implantation confers multiple advantages for the pediatric population. Beyond improved speech understanding and music appreciation, minimizing intracochlear trauma and resultant scarring facilitates potential future regenerative treatments or revision surgery.
AIMS: Contemporary guidelines differ in their recommendations regarding initiating non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) at low risk of stroke. This study aimed to examine the effectiveness and safety of NOACs for low-risk AF in a Japanese cohort.
METHODS AND RESULTS: In this retrospective cohort study based on the JMDC Claims Database extracted between April 2011 and November 2022, we identified 13 291 patients with AF at low risk of stroke. We performed inverse probability of treatment weighting Cox regression analyses to compare the embolization and bleeding risks between the nontreatment and NOAC groups. Net clinical benefit was defined as the annual incidence of ischaemic stroke events prevented by NOACs after subtracting intracranial haemorrhage (ICH) events attributable to NOACs, multiplied by a weighting factor. The incidences of stroke and ICH in the nontreatment group were 0.47 and 0.15 per 100 person-years, respectively. The NOAC group had higher incidences of ICH (hazard ratio [HR]: 1.73, 95% confidence interval [CI]: 0.75-4.00) and stroke (HR: 1.41, 95% CI: 0.84-2.36). The net clinical benefit of NOAC treatment was -0.35% per year (95% CI: -0.99-0.29%).
CONCLUSION: Non-vitamin K antagonist oral anticoagulants treatment may be associated with a slightly high risk of ICH, and it yielded a neutral clinical benefit in the present Japanese population, which provides reassurance concerning the role of ethnicity in NOAC treatment for patients with AF and suggests a need to assess comprehensive weighting of the respective risk factors.
Cancer cachexia, or the unintentional loss of body weight in patients with cancer, is a multiorgan and multifactorial syndrome with a complex and largely unknown etiology; however, metabolic dysfunction and inflammation remain hallmarks of cancer-associated wasting. Although cachexia manifests with muscle and adipose tissue loss, perturbations to the gastrointestinal tract may serve as the frontline for both impaired nutrient absorption and immune-activating gut dysbiosis. Investigations into the gut microbiota have exploded within the past two decades, demonstrating multiple gut-tissue axes; however, the link between adipose and skeletal muscle wasting and the gut microbiota with cancer is only beginning to be understood. Furthermore, the most used anticancer drugs (e.g. chemotherapy and immune checkpoint inhibitors) negatively impact gut homeostasis, potentially exacerbating wasting and contributing to poor patient outcomes and survival. In this review, we 1) highlight our current understanding of the microbial changes that occur with cachexia, 2) discuss how microbial changes may contribute to adipose and skeletal muscle wasting, and 3) outline study design considerations needed when examining the role of the microbiota in cancer-induced cachexia.
The present invention relates to novel imidazolidine derivatives of formula in which A, E, Z, R1, R2, R3, R4 and R5 have the meanings indicated in the description. The compounds of formula (I) are valuable pharmaceutical active compounds, which are suitable, for example, for the treatment of inflammatory diseases, for example of rheumatoid arthritis, or of allergic diseases. The compounds of the formula (I) are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the treatment of diseases which are caused by an undesired extent of leukocyte adhesion, and/or leukocyte migration or are assosiated therewith or in which cell-cell or cell-matrix interactions which are based on the interactions of VLA-4 receptors with their ligands play a role. The invention furthermore relates to processes for the preparation of the compounds of formula (I), their use and pharmaceutical preparations which contain compounds of formula (I). 16 claims
Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback \& Building Motivation; Session 2: Building Motivation \& Skill Selection and Practice; Session 3: Developing Change Plan \& Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation \& Skill Practice.
Diarrhea, including severe and life-threatening diarrhea requiring hospitalization, can occur with HYCAMTIN capsules. Diarrhea can occur at the same time as drug-induced neutropenia and its sequelae. In the 682 patients who received HYCAMTIN capsules in the four lung cancer trials, the incidence of diarrhea caused by HYCAMTIN capsules was 22%, including Grade 3 (4%) and Grade 4 (0.4%). The incidence of Grade 3 or 4 diarrhea proximate (within 5 days) to Grade 3 or 4 neutropenia was 5%. The median time to onset of Grade 2 to 4 diarrhea was 9 days in the group receiving HYCAMTIN capsules.

Monitor patients for diarrhea and treat with antidiarrheals at the first sign of diarrhea. Withhold and dose reduce as recommended based on severity [see Dosage and Administration (2.2)].
PURPOSE:To obtain uniform human macrophage activation factor (MAF) stably in large quantity, by culturing human T cell hybridoma and separating and purifying the supernatant liquid of the culture product by conventional method. CONSTITUTION:A human leukemia T cell strain is treated with a protein synthesis inhibitor or its combination with an RNA synthesis inhibitor. Separately human T cell is stimulated with mitogen or antigen. Both cells are fused together in the presence of a fusion promoter and the resultant fused cell is exclusively separated and cloned to obtain an MAF-producing human T cell hybridoma. The human T cell hybridoma is cultured and the objective MAF is separated from the supernatant liquid of the culture product. The MAF has the following properties. (i) Acting to human and mouse macrophage to induce anti-tumor macrophage, (ii) acting to macrophage to produce tumor cytotoxic factor from the macrophage, (iii) having a molecular weight of 40,000-150,000 and an isoelectric point of 4.6+ or -0.2 and (iv) resistant to inactivation by the treatment at 2 pH or 56 deg.C for 30min.
PROBLEM TO BE SOLVED: To obtain the subject new compound having excellent washability and foamability even under acidic to weakly alkaline conditions and even in hard water having high hardness, good in defoaming activity on rinse and in touch, little in irritativeness against hair and skin and having an excellent anionic surface-activating performance as a component for detergents. SOLUTION: A compound of formula I (R is a 6-30C linear or branched alkyl or alkenyl; X is a group of formula II or III; Y is H, CH2 COOM; Z is CH2 COOM, CH3 ; M is H, a salt-forming cation), e.g. monohydroxylauryl ether lactic acid sodium salt. The compound of formula I is obtained e.g. by reacting the lower alcohol ester of lactic acid, malic acid or citric acid as a hydroxycarboxylic acid with an epoxyalkane or epoxyalkene in the presence of a basic catalyst and subsequently saponifying the product with an alkali. The reaction of the hydroxycarboxylic acid ester with the epoxyalkane or epoxyalkene is preferably carried out in a polar solvent at 100-150 deg.C.